UBS Group Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $188.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lifted by UBS Group from $173.00 to $188.00 in a research report released on Tuesday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other brokerages have also issued reports on SRPT. Needham & Company LLC restated a buy rating and set a $235.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Barclays cut their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an overweight rating for the company in a research report on Thursday, August 8th. Citigroup decreased their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a neutral rating on the stock in a report on Thursday, August 8th. Bank of America boosted their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a buy rating in a report on Friday, June 21st. Finally, Robert W. Baird raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an outperform rating in a research note on Friday, June 21st. Three analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of Moderate Buy and a consensus target price of $187.39.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $127.10 on Tuesday. The firm has a fifty day simple moving average of $138.26 and a two-hundred day simple moving average of $132.61. The firm has a market cap of $12.01 billion, a PE ratio of 1,155.45 and a beta of 0.81. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. Sarepta Therapeutics’s revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) earnings per share. On average, equities analysts anticipate that Sarepta Therapeutics will post 1.47 EPS for the current year.

Insider Buying and Selling

In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction dated Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 52,801 shares of company stock worth $8,399,586. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. Riggs Asset Managment Co. Inc. grew its holdings in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares during the period. EP Wealth Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after acquiring an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after acquiring an additional 120 shares during the period. Finally, WCM Investment Management LLC grew its position in Sarepta Therapeutics by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after acquiring an additional 142 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.